CancerDrs

Lymphoma clinical trials in Utah

24 actively recruiting lymphoma trials at 1 site across Utah.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
  • Primary Children's Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be m…

Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091254
Sites in Utah:
  • Huntsman Cancer Institute - Oncology Division — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Utah:
  • Primary Children's Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back a…

Sponsor: PedAL BCU, LLC
NCT ID: NCT04726241
Sites in Utah:
  • Primary Children's Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Network

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…

Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may st…

Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT04803201
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal re…

Sponsor: Allogene Therapeutics
NCT ID: NCT06500273
Sites in Utah:
  • Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
  • Intermountain Health LDS Hospital — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory…

Sponsor: Curis, Inc.
NCT ID: NCT03328078
Sites in Utah:
  • Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)

This is a study for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with a BTK inhibitor (covalent and non-covalent) and a BCL-2 inhibito…

Sponsor: Nurix Therapeutics, Inc.
NCT ID: NCT07221500
Sites in Utah:
  • University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with tacabrutideg in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignan…

Sponsor: BeOne Medicines
NCT ID: NCT06634589
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), diffuse lar…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06395103
Sites in Utah:
  • Intermountain - Primary Children's Hospital ( Site 1014) — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to avai…

Sponsor: VM Oncology, LLC
NCT ID: NCT03556228
Sites in Utah:
  • Utah Cancer Specialists (site 203) — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back after a period of improvement (relapsed) or that has not responded to …

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07061951
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma. Glofitamab and obinutuzumab ar…

Sponsor: City of Hope Medical Center
NCT ID: NCT05861050
Sites in Utah:
  • Huntsman Cancer Institute — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting NIH

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06860594
Sites in Utah:
  • Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up…

Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT04771572
Sites in Utah:
  • University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia

This study will assess the safety, tolerability, pharmaokinetics, and preliminary efficacy of mosunetuzumab (Lunsumio) monotherapy in participants with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic ly…

Sponsor: Hoffmann-La Roche
NCT ID: NCT05091424
Sites in Utah:
  • Huntsman Cancer Institute at The University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Industry

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecu…

Sponsor: Newave Pharmaceutical Inc
NCT ID: NCT04775745
Sites in Utah:
  • Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Phase 1 Recruiting Academic/Other

Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR)

The purpose of this clinical trial is to learn if drugs loncastuximab tesirine and rituximab (lonca-R) after stereotactic radiosurgery are safe and effective for treatment of central nervous system lymphomas.

Sponsor: University of Utah
NCT ID: NCT06607549
Sites in Utah:
  • Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Recruiting NIH

Collection of Tissue Samples for Cancer Research

Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To ob…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT00900198
Sites in Utah:
  • University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
Recruiting Network

Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers

This study collects blood and tissue samples for research of human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS)-related cancers. Collecting blood and tissue samples and studying biomarkers in the laboratory may he…

Sponsor: AIDS Malignancy Consortium
NCT ID: NCT05663502
Sites in Utah:
  • Huntsman Cancer Institute, University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →
NA Recruiting Academic/Other

Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy

The proposed multimodal telerehabilitation model allows a rehabilitation therapy team to set up individualized rehabilitation plans using a web-based care management portal and monitor patient progress online. Patients at home follow a saf…

Sponsor: University of Utah
NCT ID: NCT07390071
Sites in Utah:
  • Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-09-07